Survival prediction based on qualitative MRI diffusion signature in patients with recurrent high grade glioma treated with bevacizumab

BACKGROUND: Bevacizumab was approved by the FDA for the treatment of recurrent or progressive glioblastoma (GBM). Imaging responses are typically assessed by gadolinium-enhanced MRI. We sought to determine the significance of qualitative diffusion signature (manifest as variable degree of dark signa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Quant Imaging Med Surg
Main Authors: Goyal, Pradeep, Tenenbaum, Mary, Gupta, Sonali, Kochar, Puneet S., Bhatt, Alok A., Mangla, Manisha, Kumar, Yogesh, Mangla, Rajiv
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5941208/
https://ncbi.nlm.nih.gov/pubmed/29774180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/qims.2018.04.05
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados